Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  mixed glioma, adult
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 36 for your search:
Start Over
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, 2868, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1174, NCI-2012-01989, CDR0000737109, NCCTG-N1174, NCT01648348
Carboxyamidotriazole Orotate with or without Bevacizumab in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00044274, NCI-2014-00031, NCT01954030
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, NCT01977677
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG221-C-003, NCI-2015-01170, NCT02273739
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Aminolevulinic Acid in Measuring Brain Tumors in Patients With High Grade Glioma Undergoing Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 to 72
Trial IDs: 10101, NCI-2011-01264, NCT01116661
Nilotinib in Treating Patients with Recurrent Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCT01140568
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas and Favorable Grade 3 Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-439, NCI-2011-00915, NCT01358058
Everolimus With or Without Temozolomide in Treating Patients With Newly-Diagnosed Low-Grade Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 131012, NCI-2014-00749, 081184, CRAD001CUS225T, NCT02023905
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08109, NCI-2011-01701, NCT00823459
Pegylated Liposomal Irinotecan in Treating Patients With Recurrent High-Grade Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08103, NCI-2011-01271, H5941-32646, UCSF-H5941-32646-01, UCSF-08103, H5941-32646-01, NCT00745082, NCT00734682
Plerixafor and Bevacizumab in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-329, NCI-2012-00149, MAMO0909-6, NCT01339039
Hypofractionated Stereotactic Radiotherapy and Bevacizumab in Treating Patients with Recurrent Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-057, NCI-2011-01329, NCT01392209
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Mebendazole and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: J1194, NCI-2013-00047, NCT01729260
Viral Therapy before and during Surgery and Flucytosine after Surgery in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: Tg 511-13-01, NCI-2014-02478, TOG1314, NCT01985256
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: ATI001-102, NCI-2014-00752, NCT02026271
Start Over